Dr. Axel Ullrich, Director at the Max Planck Institute of Biochemistry, chooses Proteros as preferred service partner for kinase drug discovery

22-Feb-2011 - Germany

Proteros Biostructures GmbH and Max Planck Institute (“MPI”) of Biochemistry, Martinsried announced that Dr. Axel Ullrich has chosen Proteros as the preferred service partner to support kinase drug discovery research at the Department of Molecular Biology.

Proteros will develop kinase-focused assay systems and provide screening services employing its proprietary platform for screening to support the validation of novel kinase targets for drug discovery.

Dr. Axel Ullrich, co-founder of four drug discovery companies and key researcher in the development of two successfully marketed kinase drugs said that he has chosen Proteros as preferred partner for his continued drug discovery projects. Dr. Ullrich stated that he has successfully cooperated with Proteros on several projects during the past few years and is pleased with Proteros’ performance. Moreover he stated, “Proteros has proven to be a reliable and flexible partner with expertise in characterizing compound-target interactions and in the development of biochemical and cellular assay technologies.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances